Imperagen, a Manchester-based biotech firm, has raised £5 million in seed funding to boost its work on enzyme engineering using AI and quantum physics. The company aims to speed up the development of enzymes, which are used in industries ranging from pharmaceuticals to sustainable chemicals. Traditional methods of enzyme design rely on manual screening, a process that is slow, costly, and has limited success rates. Imperagen’s approach merges quantum simulations, AI training, and robotic testing into one system, cutting time and costs.
The firm was founded in 2021 by researchers from the Manchester Institute of Biotechnology. Its platform uses quantum physics to model millions of enzyme mutations virtually, generating data that trains AI models. These models then guide automated lab experiments, which in turn refine the AI’s predictions. This closed-loop system reduces trial-and-error in enzyme development, a process that often takes years with conventional methods.
Related: What Is a PEO? Exploring Professional Employer Organizations and Their Benefits
The £5 million round was led by PXN Ventures, with support from existing investors IQ Capital and Northern Gritstone. Funds will expand Imperagen’s R&D, scale its lab operations, and grow its AI team. The company also plans to invest in sales and marketing to turn interest from industries like pharmaceuticals and personal care into revenue.
Imperagen’s CEO, Guy Levy-Yurista, said the company’s success hinges on being AI-native, data-driven, and impactful. “We combine deep technology with real-world applications,” he said. The firm’s team and location in Manchester, he added, give it a unique edge. The company’s focus on sectors like industrial biotech and sustainable chemicals aligns with growing demand for greener manufacturing processes.
Related: How To Choose Web Design Services: Efficient & Quality Assured?
Enzymes are key to reducing waste and energy use in production. For example, in pharmaceutical manufacturing, they can cut the number of chemical steps needed to make drugs. Imperagen’s platform aims to make this process faster, allowing companies to bring better products to market more quickly. The firm’s approach could lower costs and improve efficiency across multiple industries.
The investment comes as interest in AI-driven biotechnology grows. Other startups are using machine learning for drug discovery, but Imperagen’s integration of quantum physics and robotics sets it apart. The company’s ability to generate and test enzyme designs rapidly may give it a competitive edge in a crowded field. Its focus on practical applications, rather than theoretical research, could attract partners looking for immediate results.
Related: Plastic Manufacturing in Malaysia: A Comprehensive Overview
Imperagen’s next steps include refining its platform and proving its technology’s scalability. The company plans to work with early adopters in life sciences and chemicals to demonstrate its value. If successful, the model could be applied to other areas, such as biofuels or food production. The £5 million will also help build a team capable of handling both technical and commercial challenges.
The biotech sector has seen a surge in funding for AI tools, but few companies have integrated quantum physics into their workflows. Imperagen’s approach may face skepticism from traditionalists who question the reliability of virtual models. However, the firm’s emphasis on experimental validation through robotics could address these concerns. Its ability to translate theoretical predictions into lab results will be a key test of its technology.